PI: Andreas Reinisch
Focus: The research group led by Andreas Reinisch focuses on investigating genetic and molecular events that contribute to the development of clonal hematopoiesis and subsequently lead to the formation of myeloid leukemias. A central aspect of our work is the targeted introduction of genetic alterations (mutations) into normal hematopoietic stem and progenitor cells using CRISPR/Cas9 technology. The goal is to understand how specific genetic changes promote the development of leukemic stem cells, selectively favor their growth, and ultimately lead to the manifestation of leukemia.
In addition, we are dedicated to studying the contribution of clonal hematopoiesis to the development of atherosclerosis and cardiovascular diseases. Through the development and use of a new humanized mouse model that accurately replicates human hematopoiesis and atherosclerotic processes, we aim to better understand the underlying mechanisms.
Another major focus of our research is the study of the interaction between the bone marrow microenvironment, the so-called bone marrow niche, and both normal and malignant hematopoietic cells. We investigate how the bone marrow environment contributes to leukemogenesis and to what extent leukemia itself can alter its microenvironment.
To address these specific research questions, our group places great emphasis on the development and application of innovative methods. Among other things, we use humanized mouse models and customized gene-editing technologies for human primary tissue. Additionally, we employ a wide array of cutting-edge assays to evaluate the function and potential of hematopoietic stem and progenitor cells, aiming to better understand the underlying mechanisms of leukemogenesis and develop potential new therapeutic approaches.
A unique feature of our research, and an important translational aspect of our work, is the use and study of primary patient samples, made possible through close collaboration with the Leukemia Biobank. Through our strong network of national and international partners, as well as the utilization of the infrastructure at the Medical University of Graz, we contribute to translating preclinical findings into clinical research and improving treatment options for patients with hematological diseases.
